Evaluation of the cardiac and metabolic effects of semaglutide in heart failure with preserved ejection fraction (CAMEO-SEMA) a phase II, prospective, double-blind randomized trial
A meta-analysis of GLP-1RA CVOT showed that treatment with GLP-1RA reduced the risk of developing a composite kidney outcome including new-onset MA by 21% compared to placebo (HR 0.79, 95% CI 0.73-0.87), with only ELIXA and EXSCEL not achieving significant benefit [11]
For the documented adverse-event profile from published trials, see our retatrutide side effects breakdown
Prevents cell death: Taurine acts as an osmolyte, maintaining osmotic pressure in cells as ion concentrations fluctuate in the brain
UV exposure triggers cascading damage through reactive oxygen species (ROS) generation, MMP activation, and inflammatory signalling, ultimately leading to collagen fragmentation and elastin disorganisation